3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Breast Neoplasms
20
Colorectal Neoplasms
5
HER2-positive Breast Cancer
4
Brain Neoplasms
4
Neoplasms
3
Meningeal Neoplasms
3
Triple Negative Breast Neoplasms
2
Stomach Neoplasms
2
Neoplasm Metastasis
2
Multiple Myeloma
2
Lymphoma, Non-Hodgkin
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urologic Neoplasms
1
Rectal Neoplasms
1
Pathologic Complete Response
1
Metastatic Breast Cancer With a Isolated Brain Progression
1
Meningeal Carcinomatosis
1
Hemangiosarcoma
1
HER2-positive Metastatic Breast Cancer
1
Gallbladder Neoplasms
1
Esophageal Neoplasms
1
Colonic Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Non-Small-Cell Lung
1
Biliary Tract Neoplasms
1
Anatomic Stage II Breast Cancer AJCC v8
1
Anatomic Stage IA Breast Cancer AJCC v8
1
Adenocarcinoma Of Esophagus
1
Adenocarcinoma
1
Interventions
Cisplatin
6
pembrolizumab
5
Nivolumab
5
palbociclib
4
durvalumab
4
Pemetrexed
4
atezolizumab
3
abemaciclib
3
Fulvestrant
3
Carboplatin
3
Anastrozole
3
130-nm albumin-bound paclitaxel
3
selpercatinib
2
ribociclib
2
relatlimab
2
entrectinib
2
cobimetinib
2
capmatinib
2
alectinib
2
Vemurafenib
2
Radiosurgery
2
Paclitaxel
2
Letrozole
2
Gonadotropin-Releasing Hormone
2
Gemcitabine
2
Bevacizumab
2
AZD9833
2
trametinib
1
taletrectinib
1
spartalizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Neoplasms by Site
×
tucatinib
×
1 year
×
Clear all
No trials found.